ClinicalTrials.gg
CompletedNCT04194151Updated Aug 12, 2020Results posted

Impact of Propofol Reduction in Anesthesia Induction

A Phase 4 interventional study of Propofol Injection in Propofol Adverse Reaction and Anesthesia, sponsored by Hospital Central de la Defensa Gómez Ulla. Completed at 1 site in Spain. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-08-12.

Sponsored by Hospital Central de la Defensa Gómez Ulla · Phase 4, Interventional, and Supportive care

How we know

From the registry’s dates

  • Registered 2 years 1 month after the study started (first participant enrolled Nov 2017, registered Dec 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
192
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Objective: Determine if, by reducing the dose of propofol and increasing the time elapsed between fentanyl and propofol administration, hemodynamic response is improved.

Methods: Patients were randomized into time groups (2 and 1 minute) and each subdivided into dose groups (1, 1.5 and 2 mg kg-1) obtaining six time-dose groups. After receiving 2 μg kg-1 of fentanyl, propofol was administered after the predetermined time. Time to hypnosis (BIS\<60) and hemodynamic parameters at pre-induction, pre-intubation and postintubation were registered.

Read the detailed description

A minimum of 162 patients were required, considering an expected Mean Difference of 5 with expected Standard Deviation of 22, confidence level of 95% and power of 80%. Estimating a possible loss of 15%, it was raised to 192. Consecutive identification numbers were assigned and the sample was randomized in six groups of 32 patients according to time and dose of propofol.

Pre-oxygenation was performed until the expired oxygen fraction exceeded 80% and 2 µg/kg of intravenous fentanyl were administered. Depending on the study group, 1 or 2 minutes were allowed to pass and 1, 1.5 or 2 mg/kg of propofol were supplied (prior administration of intravenous lidocaine 0.5 mg/kg). The time in which the BIS dropped below 60 was recorded. If it did not reach that level after two minutes or when it exceeded it but then rose above 60 again, an extra dose of propofol of 0.5 mg/kg was administered. Muscle relaxation was performed with rocuronium 0.6 mg/kg. The patient was manually ventilated until endotracheal intubation was performed by the same experienced anaesthesiologist and connected to mechanical ventilation.

Data were collected manually. Statistical analysis was performed using SPSS ver. 22. Inferential statistics were performed using t-test for quantitative variables, chi-square for qualitative and ANOVA for qualitative and quantitative comparisons. Non-parametric statistical tests were used when necessary. Confidence intervals were estimated at a level of 95% and a P value of \<.05 was considered statistically significant.

02

Conditions studied

  • Propofol Adverse Reaction
  • Anesthesia

Keywords

  • propofol synergy
  • fentanyl
  • anesthesia induction
03

In context

Lead sponsor

Hospital Central de la Defensa Gómez Ulla is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults who required general anesthesia
  • General anesthesia with endotracheal intubation (no supraglottic devices)
  • Signed
  • Non-cardiac surgery
  • Same anesthesiologist

Exclusion criteria

Exclusion Criteria:

  • Hemodynamic instability (systolic BP \< 90 mmHg with clinical signs of low cardiac output: impaired consciousness, diuresis \<0.5 ml/kg/h, central venous saturation \<60% with normal arterial saturation or lactate >3 mmol/l)
  • Increased risk of bronchoaspiration (absence of fasting, stomach retention, intestinal obstruction, pregnancy, etc.)
  • Suspected difficult airway
  • Known allergy to anesthetic drugs
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
192 participants (actual)

Study arms

  • Active comparator
    2 minute - 2 mg/kg group

    2 mcg/kg of fentanyl administrated intravenously. wait for 2 minutes to inject 2 mg/kg of propofol

    Drug: Propofol Injection

  • Active comparator
    2 minute - 1,5 mg/kg group

    2 mcg/kg of fentanyl administrated intravenously. wait for 2 minutes to inject 1,5 mg/kg of propofol

    Drug: Propofol Injection

  • Active comparator
    2 minute - 1 mg/kg group

    2 mcg/kg of fentanyl administrated intravenously. wait for 2 minutes to inject 1 mg/kg of propofol

    Drug: Propofol Injection

  • Active comparator
    1 minute - 2 mg/kg group

    2 mcg/kg of fentanyl administrated intravenously. wait for 1 minute to inject 2 mg/kg of propofol

    Drug: Propofol Injection

  • Active comparator
    1 minute - 1,5 mg/kg group

    2 mcg/kg of fentanyl administrated intravenously. wait for 1 minute to inject 1,5 mg/kg of propofol

    Drug: Propofol Injection

  • Active comparator
    1 minute - 1 mg/kg group

    2 mcg/kg of fentanyl administrated intravenously. wait for 1 minute to inject 1 mg/kg of propofol

    Drug: Propofol Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Systolic Blood Pressure Variation

    Non-invasive systolic blood pressure change (%) at baseline, pre-intubation and postintubation. Positive results mean percentage reduction in SBP between the studied moments. Negative results mean percentage increase in SBP between the studied moments.

    Time frame: Baseline before fentanyl administration, pre-intubation after propofol and bispectral index<60 and postintubation 15 seconds after endotracheal tube positioned

  2. Heart Rate Variation

    Heart rate change (%) registered at baseline, pre-intubation and postintubation. Positive results mean percentage reduction in HR between the studied moments. Negative results mean percentage increase in HR between the studied moments.

    Time frame: Baseline before fentanyl administration, pre-intubation after propofol and bispectral index<60 and postintubation 15 seconds after endotracheal tube positioned

  3. Systolic Blood Pressure Variation in Elderly (>55y)

    Non-invasive SBP change (%) in patients \> 55 years at baseline, pre-intubation and postintubation. Positive results mean percentage reduction in SBP between the studied moments. Negative results mean percentage increase in SBP between the studied moments.

    Time frame: Baseline before fentanyl administration, pre-intubation after propofol and bispectral index<60 and postintubation 15 seconds after endotracheal tube positioned

Secondary outcomes

  1. Time to Hypnosis

    Bispectral index (BIS)\<60 meaning "general anesthesia", BIS\>60 meaning mild/moderate sedation. We measure the time until patient reachs hypnosis

    Time frame: After administration of propofol, time is measured in seconds until BIS values are less than 60

  2. Number of Patients Who Needed Vasoactive Drug

    Patients who suffered SPB reduction \> 30% or SPB \< 90mmHg, receive vasoactive drugs

    Time frame: 1 minute after intubation

07

Results

Posted Aug 12, 2020
Limitations and caveats
Pediatric population not included. BMI not registrated. Type of surgery not registered.

Participant flow

Every patient who agreed to participate and required general anesthesia with endotracheal intubation by the same anesthesiologist

Participant flow — Overall Study
Milestone2 Minute - 2 mg/kg Group2 Minute - 1,5 mg/kg Group2 Minutes - 1 mg/kg Group1 Minute - 2 mg/kg Group1 Minute - 1,5 mg/kg Group1 Minute - 1 mg/kg Group
Started323232323232
Completed313031313231
Not completed121101
Withdrew: Physician decision111101
Withdrew: Monitorization problem010000

Outcome measures

PrimarySystolic Blood Pressure Variation

Non-invasive systolic blood pressure change (%) at baseline, pre-intubation and postintubation. Positive results mean percentage reduction in SBP between the studied moments. Negative results mean percentage increase in SBP between the studied moments.

Time frame:
Baseline before fentanyl administration, pre-intubation after propofol and bispectral index<60 and postintubation 15 seconds after endotracheal tube positioned
Reported as:
Mean · percentage of variation
Systolic Blood Pressure Variation
percentage of variation2 Minute - 2 mg/kg Group2 Minute - 1,5 mg/kg Group2 Minute - 1 mg/kg Group1 Minute - 2 mg/kg Group1 Minute - 1,5 mg/kg Group1 Minute - 1 mg/kg Group
SBP baseline/pre-intubation26 ± 1623 ± 1218 ± 1322 ± 1118 ± 1317 ± 13
SBP baseline/postintubation11 ± 228 ± 159 ± 1914 ± 1816 ± 198 ± 16
SBP pre-intubation/postintubation-22 ± 27-21 ± 28-12 ± 17-12 ± 21-3 ± 16-12 ± 16
PrimaryHeart Rate Variation

Heart rate change (%) registered at baseline, pre-intubation and postintubation. Positive results mean percentage reduction in HR between the studied moments. Negative results mean percentage increase in HR between the studied moments.

Time frame:
Baseline before fentanyl administration, pre-intubation after propofol and bispectral index<60 and postintubation 15 seconds after endotracheal tube positioned
Reported as:
Mean · percentage of variation
Heart Rate Variation
percentage of variation2 Minute - 2 mg/kg Group2 Minute - 1,5 mg/kg Group2 Minute - 1 mg/kg Group1 Minute - 2 mg/kg Group1 Minute - 1,5 mg/kg Group1 Minute - 1 mg/kg Group
HR baseline/pre-intubation6 ± 134 ± 84 ± 101 ± 114 ± 155 ± 14
HR baseline/postintubation-10 ± 19-8 ± 15-9 ± 16-4 ± 17-5 ± 20-10 ± 18
HR pre-intubation/postintubation-17 ± 19-12 ± 16-15 ± 20-5 ± 16-10 ± 19-17 ± 19
PrimarySystolic Blood Pressure Variation in Elderly (>55y)

Non-invasive SBP change (%) in patients \> 55 years at baseline, pre-intubation and postintubation. Positive results mean percentage reduction in SBP between the studied moments. Negative results mean percentage increase in SBP between the studied moments.

Time frame:
Baseline before fentanyl administration, pre-intubation after propofol and bispectral index<60 and postintubation 15 seconds after endotracheal tube positioned
Reported as:
Mean · percentage of variation
Systolic Blood Pressure Variation in Elderly (>55y)
percentage of variation2 Minute - 2 mg/kg Group2 Minute - 1,5 mg/kg Group2 Minute - 1 mg/kg Group1 Minute - 2 mg/kg Group1 Minute - 1,5 mg/kg Group1 Minute - 1 mg/kg Group
SBP baseline/pre-intubation36 ± 1226 ± 1221 ± 1329 ± 621 ± 1322 ± 13
SBP baseline/postintubation19 ± 2210 ± 1413 ± 1922 ± 1522 ± 1712 ± 13
SBP pre-intubation/postintubation-27 ± 32-23 ± 30-10 ± 16-10 ± 232 ± 13-15 ± 19
SecondaryTime to Hypnosis

Bispectral index (BIS)\<60 meaning "general anesthesia", BIS\>60 meaning mild/moderate sedation. We measure the time until patient reachs hypnosis

Time frame:
After administration of propofol, time is measured in seconds until BIS values are less than 60
Reported as:
Mean · seconds
Time to Hypnosis
seconds2 Minute - 2 mg/kg Group2 Minute - 1,5 mg/kg Group2 Minute - 1 mg/kg Group1 Minute - 2 mg/kg Group1 Minute - 1,5 mg/kg Group1 Minute - 1 mg/kg Group
Time to Hypnosis54 ± 2949 ± 2762 ± 3441 ± 2047 ± 1567 ± 42
SecondaryNumber of Patients Who Needed Vasoactive Drug

Patients who suffered SPB reduction \> 30% or SPB \< 90mmHg, receive vasoactive drugs

Time frame:
1 minute after intubation
Reported as:
Count of participants · Participants
Number of Patients Who Needed Vasoactive Drug
Participants2 Minute - 2 mg/kg Group2 Minute - 1,5 mg/kg Group2 Minute - 1 mg/kg Group1 Minute - 2 mg/kg Group1 Minute - 1,5 mg/kg Group1 Minute - 1 mg/kg Group
Number of Patients Who Needed Vasoactive Drug410230

Adverse events

Collected over Baseline until 60 seconds after endotracheal tube positioned. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
2 Minute - 2 mg/kg Group0/31 (0%)0/31 (0%)4/31 (12.9%)
2 Minute - 1,5 mg/kg Group0/30 (0%)0/30 (0%)1/30 (3.3%)
2 Minute - 1 mg/kg Group0/31 (0%)0/31 (0%)0/31 (0%)
1 Minute - 2 mg/kg Group0/31 (0%)0/31 (0%)2/31 (6.5%)
1 Minute - 1,5 mg/kg Group0/32 (0%)0/32 (0%)3/32 (9.4%)
1 Minute - 1 mg/kg Group0/31 (0%)0/31 (0%)0/31 (0%)
Most frequent other events
Most frequent other events
Event2 Minute - 2 mg/kg Group2 Minute - 1,5 mg/kg Group2 Minute - 1 mg/kg Group1 Minute - 2 mg/kg Group1 Minute - 1,5 mg/kg Group1 Minute - 1 mg/kg Group
Vasoactive drug needCardiac disorders4/311/300/312/313/320/31

Baseline characteristics

Age, Continuous
Age, Continuous(years)2 Minute - 2 mg/kg Group2 Minute - 1,5 mg/kg Group2 Minute - 1 mg/kg Group1 Minute - 2 mg/kg Group1 Minute - 1,5 mg/kg Group1 Minute - 1 mg/kg GroupTotal
Mean59 ± 2061 ± 1760 ± 1959 ± 1764 ± 1855 ± 1660 ± 18
Sex: Female, Male
Sex: Female, Male(Participants)2 Minute - 2 mg/kg Group2 Minute - 1,5 mg/kg Group2 Minute - 1 mg/kg Group1 Minute - 2 mg/kg Group1 Minute - 1,5 mg/kg Group1 Minute - 1 mg/kg GroupTotal
Female15141717181495
Male16161414141791
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)2 Minute - 2 mg/kg Group2 Minute - 1,5 mg/kg Group2 Minute - 1 mg/kg Group1 Minute - 2 mg/kg Group1 Minute - 1,5 mg/kg Group1 Minute - 1 mg/kg GroupTotal
Count of participants——————0
weight
weight(kilograms)2 Minute - 2 mg/kg Group2 Minute - 1,5 mg/kg Group2 Minute - 1 mg/kg Group1 Minute - 2 mg/kg Group1 Minute - 1,5 mg/kg Group1 Minute - 1 mg/kg GroupTotal
Mean73 ± 1677 ± 1770 ± 1571 ± 1571 ± 1573 ± 1572 ± 15
anesthesia risk (ASA), categorical
anesthesia risk (ASA), categorical(Participants)2 Minute - 2 mg/kg Group2 Minute - 1,5 mg/kg Group2 Minute - 1 mg/kg Group1 Minute - 2 mg/kg Group1 Minute - 1,5 mg/kg Group1 Minute - 1 mg/kg GroupTotal
Low risk201917211321111
High risk11111410191075
Hypertension
Hypertension(Participants)2 Minute - 2 mg/kg Group2 Minute - 1,5 mg/kg Group2 Minute - 1 mg/kg Group1 Minute - 2 mg/kg Group1 Minute - 1,5 mg/kg Group1 Minute - 1 mg/kg GroupTotal
Count of participants1591513161381
Antihypertensive treatment
Antihypertensive treatment(Participants)2 Minute - 2 mg/kg Group2 Minute - 1,5 mg/kg Group2 Minute - 1 mg/kg Group1 Minute - 2 mg/kg Group1 Minute - 1,5 mg/kg Group1 Minute - 1 mg/kg GroupTotal
Count of participants991210121163
Heart rate treatment
Heart rate treatment(Participants)2 Minute - 2 mg/kg Group2 Minute - 1,5 mg/kg Group2 Minute - 1 mg/kg Group1 Minute - 2 mg/kg Group1 Minute - 1,5 mg/kg Group1 Minute - 1 mg/kg GroupTotal
Count of participants11710911351
08

Study locations

1 site
  • Hospital central de la defensa Gomez Ulla
    Madrid, 28047, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Oct 2018, 11 months.

Results were first posted in Aug 2020, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2019
First posted
Dec 11, 2019
StartActual
Nov 1, 2017
Primary completionActual
Oct 26, 2018
CompletionActual
Oct 26, 2018
Results first posted
Aug 12, 2020
Last update
Aug 12, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04194151
Lead sponsor
Hospital Central de la Defensa Gómez Ulla
Responsible party
paula agostina vullo (Sponsor-Investigator, Hospital Central de la Defensa Gómez Ulla) — Principal investigator
First posted
Dec 11, 2019
Start date
Nov 1, 2017
Primary completion
Oct 26, 2018
Completion
Oct 26, 2018
Results posted
Aug 12, 2020
Last update
Aug 12, 2020

Study contacts

Paula A Vullo, MD
principal investigator

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Propofol

Start the discussion